The legal status of Melanotan I cannot be answered as one fact, because a single name covers two different substances with opposite standing. One is afamelanotide, a synthetic alpha-melanocyte-stimulating hormone analog approved as a prescription-only implant (Scenesse) for a rare disease; the other is an unlicensed injectable sold informally for cosmetic tanning, whose sale is prohibited across major markets. An accurate legal reading depends entirely on keeping those two meanings apart.
The name Melanotan I covers both afamelanotide, an FDA-, EMA-, and TGA-approved prescription implant for erythropoietic protoporphyria, and an unlicensed tanning peptide whose sale is prohibited across major jurisdictions.
In its approved form, Melanotan I is a genuine prescription medicine, but only under the clinical name afamelanotide and only for one rare condition. Marketed as Scenesse, it is authorized to reduce phototoxicity in adults with erythropoietic protoporphyria (EPP), an inherited disorder in which a buildup of protoporphyrin IX makes skin burn within minutes of light exposure. The authorization is tied to that single indication, so the substance is not lawfully available as a cosmetic tanning product.
Afamelanotide (marketed as Scenesse) is approved only to reduce phototoxicity in adults with erythropoietic protoporphyria, and the authorization does not extend to any cosmetic tanning use.
Regulators classify the approved product as a prescription-only biologic with tightly controlled distribution, not a general pharmacy item and not a scheduled narcotic. The restrictions flow from its status as a specialist-administered implant for a rare disease, not from any abuse-potential scheduling of the kind applied to opioids or stimulants.
The approved afamelanotide implant is classified as a prescription-only biologic restricted to specialist administration, not as a controlled substance subject to abuse-potential scheduling.
Selling unlicensed Melanotan tanning peptides is illegal across most major jurisdictions, because a substance marketed to change a physiological function such as pigmentation meets the legal definition of a medicine and requires a marketing authorization these products do not hold. The exposure does not rest on labeling alone: made outside any approved facility, the vials are unapproved and often adulterated or misbranded under the law before any tanning claim is even considered.
Because a substance marketed to stimulate pigmentation meets the legal definition of a medicine, unlicensed Melanotan tanning peptides are unauthorized drugs whose sale is prohibited across the United States, United Kingdom, European Union, and Australia.
The public warnings target the unlicensed tanning peptides, not the approved medical implant. Regulators converge on one core problem: because these vials come from unregulated sources, their contents, concentration, sterility, and purity are unverified.
The FDA and MHRA warnings apply specifically to unlicensed injectable tanning peptides, citing unverified contents, sterility, and dose from unregulated sources, and do not extend to the supervised afamelanotide implant.
The United States, Europe, and Australia each authorized afamelanotide for erythropoietic protoporphyria, but through separate processes and on their own timelines, which is normal for a global medicine. Approval by one regulator does not automatically make the product legal to sell in another country, since each market recognizes only its own authorization.
| Region | Regulator | Approval detail |
|---|---|---|
| Europe | EMA | Authorized earliest, for the EU EPP indication under the centralized procedure |
| United States | FDA | Cleared later, after an independent review of the clinical evidence |
| Australia | TGA | Registered for national supply under its own framework |
The EMA, FDA, and TGA each approved afamelanotide for erythropoietic protoporphyria through independent reviews on different timelines, so an approval status in one region cannot be assumed to hold in another.
The two names are often confused, but only one has a licensed medicine behind it. Melanotan I is the older name for afamelanotide, developed into the approved EPP implant, while Melanotan II is a different, more broadly acting peptide that has never been approved as a medicine anywhere and is linked in the informal market to added effects such as libido changes and nausea. In the online tanning market both appear on unlicensed vials, and selling either as a tanning product is prohibited on the same basis.
| Criterion | Melanotan I | Melanotan II |
|---|---|---|
| Identity | Afamelanotide, a melanocortin-1 receptor analog | Broader peptide acting at several melanocortin receptors |
| Approved form | Yes, the Scenesse implant for EPP | None anywhere |
| Unlicensed market | Sold as a tanning peptide, prohibited | Sold as a tanning peptide, prohibited |
Melanotan I (afamelanotide) has one lawful approved form as the Scenesse implant, whereas Melanotan II has no authorized therapeutic version anywhere, though both are prohibited when sold as unlicensed tanning peptides.
Personal buying, importing, or holding of Melanotan is more nuanced than the ban on selling it, and the position varies by country, so it cannot be assumed to be freely allowed. The consistent rule is that commercial supply is prohibited across major jurisdictions; where national law diverges is private possession and personal import.
Commercial supply of unlicensed Melanotan is prohibited across major jurisdictions, while personal possession and import rules diverge by country and can still trigger customs seizure of an unlicensed injectable.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan I. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
